Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 560

1.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.

2.

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group.

Arch Intern Med. 2003 Jul 14;163(13):1555-65.

PMID:
12860578
3.

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.

J Am Soc Nephrol. 2007 May;18(5):1540-6. Epub 2007 Apr 4.

4.

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.

Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K; Asian RENAAL Study Investigators.

Diabetes Care. 2004 Apr;27(4):874-9.

PMID:
15047641
5.

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Circulation. 2004 Aug 24;110(8):921-7. Epub 2004 Aug 9.

6.

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S.

Kidney Int. 2006 May;69(9):1675-82.

7.

Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.

Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. Review.

PMID:
12612946
8.
9.

Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.

Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM; RENAAL Investigators.

Kidney Int Suppl. 2002 Dec;(82):S64-7.

10.

Losartan in diabetic nephropathy.

Perico N, Ruggenenti P, Remuzzi G.

Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. Review.

PMID:
15225108
11.

The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

Zanella MT, Ribeiro AB.

Clin Ther. 2002 Jul;24(7):1019-34. Review.

PMID:
12182249
12.

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.

Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ.

Hypertension. 2011 Jul;58(1):2-7. doi: 10.1161/HYPERTENSIONAHA.111.171488. Epub 2011 May 31.

13.

Losartan and end-organ protection--lessons from the RENAAL study.

Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM; RENAAL Investigators.

Clin Cardiol. 2005 Mar;28(3):136-42.

14.

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.

Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.

Clin Exp Nephrol. 2006 Sep;10(3):193-200.

PMID:
17009077
15.

Advances in the treatment of diabetic renal disease: focus on losartan.

Rayner B.

Curr Med Res Opin. 2004 Mar;20(3):333-40. Review.

PMID:
15025842
16.
17.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

N Engl J Med. 2001 Sep 20;345(12):861-9.

18.

High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease.

Xie D, Hou FF, Fu BL, Zhang X, Liang M.

J Clin Pharmacol. 2011 Jul;51(7):1025-34. doi: 10.1177/0091270010377502. Epub 2010 Oct 26.

PMID:
20978279
19.

[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].

Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.

Ugeskr Laeger. 2001 Oct 1;163(40):5514-9. Danish.

PMID:
11601117
20.

Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).

Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D.

Am J Kidney Dis. 2014 Feb;63(2):244-50. doi: 10.1053/j.ajkd.2013.09.016. Epub 2013 Nov 6.

PMID:
24210590

Supplemental Content

Support Center